PPT-Daclatasvir

Author : tatyana-admore | Published Date : 2015-09-17

Sofosbuvir in Genotype 3 ALLY3 Study Phase 3 Treatment Naïve and TreatmentExperienced Nelson DR et al Hepatology 201561112735 Source Nelson DR et al

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Daclatasvir" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Daclatasvir: Transcript

Sofosbuvir in Genotype 3 ALLY3 Study Phase 3 Treatment Naïve and TreatmentExperienced Nelson DR et al Hepatology 201561112735 Source Nelson DR et al . + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles. DL, . et al. . N . Engl. J Med. 2015;373:714-25.. Source: . Wyles. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles DL, . et al. . N Engl J Med. 2015;373:714-25.. Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastroenterology 2015;148:355-66 . COMMAND GT2/3. COMMAND GT2/3 Study: . daclatasvir. + PEG-IFN . + RBV for genotype 2 or 3. DCV + PEG-IFN + RBV. N = 50. No. Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. . with Advanced Liver Disease. ALLY-3+ Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Leroy V, . et al. . Hepatology 2016;63:1430-41.. Source: Leroy V, et al. Hepatology . 2016;63:1430-41.. -. Beclabuvir in GT1 Patients without Cirrhosis. UNITY-1 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Poordad F, . et al. . JAMA 2015;313:1728-35.. Source: . Poordad F, et al. JAMA 2015;313:1728-35.. . Plus . Sofosbuvir. With or Without Ribavirin . for the Treatment of Chronic HCV . Genotype . 3 Infection: . Interim Results of a Multicenter . European Compassionate . Use . Program. Welzel. TM,.

Download Document

Here is the link to download the presentation.
"Daclatasvir"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.